Telisotuzumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Telisotuzumab (ABT-700) 是一种人源化重组二价抗体，针对肝细胞生长因子受体（MET）的治疗性抗体，可以高亲和力结合 c-Met 并抑制 c-Met 信号传导。Telisotuzumab 具有抗肿瘤活性。

Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity.

——

Animal Model:SCID mice with Hs746T cells Dosage:2.5-40 mg/kg Administration:i.p., twice a week, 90 days Result:Reduced total and phosphorylated c-Met as well as phosphorylated Akt and Erk.Complete tumor regression at doses above 10 mg/kg but no effective inhibition of tumor growth at doses below 5mg/kg.

——

Angiogenesis

c-Met/HGFR

c-Met/HGFR

——

——

1781223-80-0

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years